{"id":7080747,"date":"2026-11-14T10:55:40","date_gmt":"2026-11-14T10:55:40","guid":{"rendered":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747"},"modified":"2026-11-14T10:55:40","modified_gmt":"2026-11-14T10:55:40","slug":"takeda-begins-us-distribution-of-narcolepsy-type-1-drug-orzeyful","status":"publish","type":"post","link":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747","title":{"rendered":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div xmlns:default=\"http:\/\/www.w3.org\/2000\/svg\">\n<div class=\"article-image\">\n<figure class=\"article-image__container\">\n                                    <picture><source media=\"(min-width: 990px)\" srcset=\"https:\/\/www.hospitalmanagement.net\/wp-content\/uploads\/sites\/9\/2026\/11\/PT-13-11-2026-shutterstock_2516166199-770x433.jpg\"\/><source media=\"(min-width: 430px)\" srcset=\"https:\/\/www.hospitalmanagement.net\/wp-content\/uploads\/sites\/9\/2026\/11\/PT-13-11-2026-shutterstock_2516166199-940x528.jpg\"\/><img decoding=\"async\" src=\"https:\/\/www.hospitalmanagement.net\/wp-content\/uploads\/sites\/9\/2026\/11\/PT-13-11-2026-shutterstock_2516166199-430x241.jpg\" alt=\"\"\/>\n                                    <\/picture><figcaption class=\"c-featured-image__description\">Takeda announces commercial launch of Orzeyful in the US. Credit: Robert V Schwemmer\/Shutterstock.com.<\/figcaption><\/figure>\n<\/p><\/div>\n<p class=\"drop-cap\">Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1.<\/p>\n<p>The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition.<\/p>\n<div class=\"in-article-premium-insights mobile-useragent-scalar\">\n<section class=\"gms-b2b-marketing\">\n<figure><img decoding=\"async\" src=\"https:\/\/www.hospitalmanagement.net\/wp-content\/themes\/goodlife-wp-B2B\/assets\/img\/globaldata_marketing_solutions_logo.svg\" alt=\"\"\/><\/figure>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p><a href=\"https:\/\/www.globaldatamarketingsolutions.com\/\" class=\"gms-find-out-more\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t\tFind out more <span><default:svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"13\" height=\"9\" viewbox=\"0 0 13 9\" fill=\"none\"><default:path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M11.685 4.5548L1.25586 4.5548L11.685 4.5548Z\" fill=\"white\"\/><default:path d=\"M11.685 4.5548L1.25586 4.5548\" stroke=\"white\" stroke-width=\"1.03145\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/><default:path d=\"M7.85693 0.918855L11.9827 4.5731L7.85693 8.33789\" stroke=\"white\" stroke-width=\"1.03145\" stroke-linecap=\"round\" stroke-linejoin=\"round\"\/><\/default:svg><\/span><\/a><\/p>\n<\/section>\n<\/div>\n<p>Following <a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/takeda-orzeyful-oveporexton-fda-approval-type-1-narcolepsy\/\" target=\"_blank\">approval by the US Food and Drug Administration (FDA) in August 2026<\/a>, the drug received a Schedule IV controlled substance (CIV) classification.<\/p>\n<p>Distribution across the country is being managed through Accredo Specialty Pharmacy, a division of Evernorth Health Services, with licensed healthcare practitioners able to prescribe the treatment.<\/p>\n<p>Takeda is also offering patient support programmes to assist eligible adults with treatment initiation and healthcare coverage navigation.<\/p>\n<p>Takeda US business unit president Rhonda Pacheco said: \u201cWe work for decades toward the defining moments that have the potential to make a real difference for patients.<\/p>\n<p>\u201cBringing Orzeyful, a first-in-class medicine, to people living with narcolepsy type 1 in the US is one of those moments.<\/p>\n<p>\u201cWe\u2019re incredibly proud to be here, and equally focused on what comes next: supporting care and access for patients prescribed Orzeyful.\u201d<\/p>\n<p>Narcolepsy type 1 is described as a rare disorder caused by the loss of orexin-producing neurons. The condition leads to fragmented nocturnal sleep, excessive daytime sleepiness, cognitive difficulties, and cataplexy, which involves sudden and temporary muscle tone loss.<\/p>\n<p>Orzeyful functions by selectively activating orexin receptor 2 pathways to restore signalling, thereby promoting daytime wakefulness and reducing abnormal rapid eye movement sleep phenomena.<\/p>\n<p>In clinical evaluations, the most frequently reported adverse effects included insomnia, excessive saliva production, increased urinary urgency, and urinary frequency.<\/p>\n<p>Regulatory authorities in China and Japan have also approved Orzeyful for adult patients with narcolepsy type 1.<\/p>\n<p>The compound serves as the lead asset in Takeda\u2019s pipeline of orexin-focused treatments.<\/p>\n<p>Alongside Orzeyful, the company is advancing other investigational oral orexin agonists, including TAK-360, which is in clinical development for idiopathic hypersomnia, narcolepsy type 1, and narcolepsy type 2, as well as TAK-495.<\/p>\n<p>Takeda is also creating digital tools and biomarker diagnostic solutions designed to identify and differentiate narcolepsy type 1 earlier.<\/p>\n<p>Jazz Pharmaceuticals\u2019 flagship oxybate blockbuster brands Xywav and Xyrem have traditionally been the top-selling narcolepsy drugs in the US. <\/p>\n<p><!-- Newsletter banner start --><\/p>\n<p><!-- <link rel=\"stylesheet\" href=\"\"> --><\/p>\n<div class=\"grid-container\">\n<section class=\"gdm-newsletter-banner__container\">\n<div class=\"grid-x gdm-newsletter-banner__wrapper-container gdm-newsletter-banner__wrapper-container--article\">\n<div class=\"cell large-9 gdm-newsletter-banner-info__wrapper\">\n<div class=\"gdm-newsletter-banner-logo__container\">\n                    <img decoding=\"async\" src=\"https:\/\/www.hospitalmanagement.net\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\" alt=\"Email newsletter icon\"\/>\n                <\/div>\n<p><h3 class=\"gdm-newsletter-banner__heading wp-noreslt\">Sign up for our daily news round-up!<\/h3>\n<h3 class=\"gdm-newsletter-banner__sub-heading\">Give your business an edge with our leading industry insights.\u00a0<\/h3>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<\/div>\n<p><!-- Newsletter banner end --><\/p>\n<footer class=\"article-footer\">\n                                <!-- article-actions start --><\/p>\n<p><!-- .gdm-article-actions -->                                <!-- article-actions end --><br \/>\n                            <\/footer>\n<\/p><\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Takeda announces commercial launch of Orzeyful in the US. Credit: Robert V Schwemmer\/Shutterstock.com. Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1. The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7080748,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[88],"tags":[18018,20740,24325,238306,238307,238305,3022],"dealstore":[],"offerexpiration":[],"class_list":["post-7080747","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-begins","tag-distribution","tag-drug","tag-narcolepsy","tag-orzeyful","tag-takeda","tag-type"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Takeda announces commercial launch of Orzeyful in the US. Credit: Robert V Schwemmer\/Shutterstock.com. Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1. The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-14T10:55:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#article\",\"isPartOf\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/b8eaddeb20a8727558e0d0cddcca426e\"},\"headline\":\"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful\",\"datePublished\":\"2026-11-14T10:55:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#organization\"},\"image\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage\"},\"thumbnailUrl\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg\",\"keywords\":[\"begins\",\"Distribution\",\"Drug\",\"narcolepsy\",\"Orzeyful\",\"Takeda\",\"type\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\",\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\",\"name\":\"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage\"},\"image\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage\"},\"thumbnailUrl\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg\",\"datePublished\":\"2026-11-14T10:55:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage\",\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg\",\"contentUrl\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg\",\"width\":1440,\"height\":811},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/accountants4yourbusiness.co.uk\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#website\",\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/accountants4yourbusiness.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/b8eaddeb20a8727558e0d0cddcca426e\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Faccountants4yourbusiness.co.uk%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Faccountants4yourbusiness.co.uk%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/accountants4yourbusiness.co.uk\"],\"url\":\"https:\/\/accountants4yourbusiness.co.uk\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747","og_locale":"en_US","og_type":"article","og_title":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network","og_description":"Takeda announces commercial launch of Orzeyful in the US. Credit: Robert V Schwemmer\/Shutterstock.com. Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1. The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological [&hellip;]","og_url":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747","og_site_name":"Som2ny Network","article_published_time":"2026-11-14T10:55:40+00:00","og_image":[{"width":1440,"height":811,"url":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#article","isPartOf":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747"},"author":{"name":"admin","@id":"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/b8eaddeb20a8727558e0d0cddcca426e"},"headline":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful","datePublished":"2026-11-14T10:55:40+00:00","mainEntityOfPage":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/#organization"},"image":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage"},"thumbnailUrl":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg","keywords":["begins","Distribution","Drug","narcolepsy","Orzeyful","Takeda","type"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#respond"]}]},{"@type":"WebPage","@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747","url":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747","name":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful - Som2ny Network","isPartOf":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage"},"image":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage"},"thumbnailUrl":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg","datePublished":"2026-11-14T10:55:40+00:00","breadcrumb":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/accountants4yourbusiness.co.uk\/?p=7080747"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#primaryimage","url":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg","contentUrl":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/11\/PT-13-11-2026-shutterstock_2516166199.jpg","width":1440,"height":811},{"@type":"BreadcrumbList","@id":"https:\/\/accountants4yourbusiness.co.uk\/?p=7080747#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/accountants4yourbusiness.co.uk\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Takeda begins US distribution of narcolepsy type 1 drug Orzeyful"}]},{"@type":"WebSite","@id":"https:\/\/accountants4yourbusiness.co.uk\/#website","url":"https:\/\/accountants4yourbusiness.co.uk\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/accountants4yourbusiness.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/accountants4yourbusiness.co.uk\/#organization","name":"Som2ny Network","url":"https:\/\/accountants4yourbusiness.co.uk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/logo\/image\/","url":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/accountants4yourbusiness.co.uk\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/b8eaddeb20a8727558e0d0cddcca426e","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/accountants4yourbusiness.co.uk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Faccountants4yourbusiness.co.uk%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Faccountants4yourbusiness.co.uk%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/accountants4yourbusiness.co.uk"],"url":"https:\/\/accountants4yourbusiness.co.uk\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/7080747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7080747"}],"version-history":[{"count":0,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/7080747\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=\/wp\/v2\/media\/7080748"}],"wp:attachment":[{"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7080747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7080747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7080747"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=7080747"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/accountants4yourbusiness.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=7080747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}